Abstract:Huanhuan Wang, 1, &ast Dan Xiao, 2, &ast Hua Zhou, 3, &ast Shu Chen, 4 Guangjun Xiao, 4 Juan Hu, 4 Hui Quan, 2 Miao Luo, 5 Shaocheng Zhang 2, 6 1 School of Laboratory Medicine, Chengdu Medical College, Chengdu, Sichuan, People's Republic of China; 2 Department of Laboratory Medicine, the Second Affiliated Hospital of Chengdu Medical College (Nuclear Industry 416 Hospital), Chengdu, Sichuan, People's Republic of China; 3 Department of Laboratory Medicine, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China; 4 Department of Laboratory Medicine, Suining Central Hospital, Suining, Sichuan, People's Republic of China; 5 Department of Laboratory Medicine, the People's Hospital of Yubei District of Chongqing, Chongqing, People's Republic of China; 6 School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shaocheng Zhang; Miao Luo, Email ; Purpose: Visceral adiposity is a significant risk factor for severe COVID-19. However, the impact of the Chinese visceral adiposity index (CVAI) on the efficacy of SARS-CoV-2 vaccines remains poorly understood. This study aims to explore the impact of CVAI on the production of neutralizing antibodies (NAb) in inactivated SARS-CoV-2 vaccines and the potential mechanism, thereby optimizing vaccination guidance. Methods: In this cross-sectional study, 206 health workers (completed two SARS-CoV-2 vaccination on February 8th and March 10th, 2021, respectively) were recruited. All baseline anthropometric parameters of the participants were collected, and venous blood samples were obtained 6 weeks later to measure peripheral innate immune cells, inflammatory cytokines, and NAb titers against SARS-CoV-2. CVAI were calculated according to the formula and divided participants into two groups depending on CVAI median. Results: The median NAb titer among healthcare workers was 12.94 AU/mL, with an efficacy of 87.86% for the SARS-CoV-2 vaccine. NAb titers were lower in the CVAI dysfunction group than in the CVAI reference group (median: 11.40 AU/mL vs 15.57 AU/mL), the hsCRP levels (median: 0.50 mg/L vs 0.30 mg/L) and peripheral monocyte count (mean: 0.47 × 10 9 /L vs 0.42 × 10 9 /L) in the CVAI dysfunction group were higher than in the CVAI reference group. Additionally, CVAI showed positive correlations with hsCRP, monocytes, lymphocytes, and B-lymphocytes, and a negative correlation with NAb titers. Conclusion: CVAI may inhibit SARS-CoV-2 neutralizing antibody expression through inducing immune dysfunction and chronic inflammation. Thus, more attention should be paid to the vaccination for high CVAI population to improve the effectiveness of vaccination, which could provide more robust support for COVID-19 epidemic prevention and control. Keywords: Chinese visceral adiposity index, immune function, chronic inflammation, SARS-CoV-2 vaccine, neutralizing antibody The coronavirus disease (COVID-19) outbreak has ended, but sporadic cases still exist around the world and the virus strain continues to mutate. As of March 24th, 2024, the coronavirus disease (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has infected 775.13 million people and caused 7.04 million deaths worldwide. 1 Chinese Center for Disease Control and Prevention indicated COVID-19 positive rate has risen from 3.3% (in the 5th week of 2024) to 14.3% (in the 9th week of 2024) in China. 2 The risk of contracting COVID-19 is never far away, and continues to pose a threat to global public health and socio-economic development. Vaccination can reduce the incidence rates, severe cases, and mortality rates, making it the most cost-effective measure for controlling the COVID-19 pandemic. 3–8 The COVID-19 vaccine activates B cells to differentiate into plasma cells and produces neutralizing antibodies primarily targeting the Spike protein. This process blocks the Spike protein receptor-binding domain (RBD) binding to host cell's angiotensin-converting enzyme 2 (ACE2), preventing the invasion of SARS-CoV-2 into cells. 9,10 At the same time, activated helper T cells (CD4 + ) secrete cytokines, activated B lymphocytes and activated killer T cells (CD8 + ) play cytotoxic role. However, the production of antibodies after vaccination is affected by many factors such as genetic factors, environmental factors and one's own state. Our preliminary research showed obesity and air pollut -Abstract Truncated-

COVID‐19 mRNA vaccine, but not a viral vector‐based vaccine, promotes neutralizing anti‐type I interferon autoantibody production in a small group of healthy individuals

No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines

Autoantibodies against type I interferons in COVID-19 infection: a systematic review and meta-analysis

COVID-19-neutralizing antibodies predict disease severity and survival

A Commentary of “type I Interferon Deficiency Can Lead to Severe COVID-19” in 10 Remarkable Discoveries from 2020 in Nature

COVID-19 neutralizing antibodies predict disease severity and survival

Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients

Immune Interference in Effectiveness of Influenza and COVID-19 Vaccination

Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia

Gonadal androgens are associated with decreased type I interferon production by plasmacytoid dendritic cells and increased IgG titres to BNT162b2 following co-vaccination with live attenuated influenza vaccine in adolescents

COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs

Neutralizing antibody levels detected early after mRNA-based vaccination do not predict by themselves subsequent breakthrough infections of SARS-CoV-2

The detectable anti-interferon-γ autoantibodies in COVID-19 patients may be associated with disease severity

COVID-19 mRNA Vaccines: The Molecular Basis of Some Adverse Events

Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome

Distinct Immune Cell Dynamics Correlate with the Immunogenicity and Reactogenicity of SARS-CoV-2 mRNA Vaccine

Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis

Visceral Adiposity and Neutralizing Antibody Expression: An Adult-Based Cross-Sectional Study

IL-1 receptor 1 signaling shapes the development of viral antigen-specific CD4+ T cell responses following COVID-19 mRNA vaccination

Transient anti-interferon autoantibodies in the airways are associated with efficient recovery from COVID-19

Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk